Creating Patient-Specific Neural Cells for the In Vitro Study of Brain Disorders.
- Authors
- Brennand, Kristen J; Marchetto, M Carol; Benvenisty, Nissim; BrΓΌstle, Oliver; Ebert, Allison; Izpisua Belmonte, Juan Carlos; Kaykas, Ajamete; Lancaster, Madeline A; Livesey, Frederick J; McConnell, Michael J; McKay, Ronald D; Morrow, Eric M; Muotri, Alysson R; Panchision, David M; Rubin, Lee L; Sawa, Akira; Soldner, Frank; Song, Hongjun; Studer, Lorenz; Temple, Sally; Vaccarino, Flora M; Wu, Jun; Vanderhaeghen, Pierre; Gage, Fred H; Jaenisch, Rudolf
- Year
- 2015
- Journal
- Stem cell reports
- PMID
- 26610635
- DOI
- 10.1016/j.stemcr.2015.10.011
- PMCID
- PMC4881284
As a group, we met to discuss the current challenges for creating meaningful patient-specific in vitro models to study brain disorders. Although the convergence of findings between laboratories and patient cohorts provided us confidence and optimism that hiPSC-based platforms will inform future drug discovery efforts, a number of critical technical challenges remain. This opinion piece outlines our collective views on the current state of hiPSC-based disease modeling and discusses what we see to be the critical objectives that must be addressed collectively as a field.
Current Challenges for Creating Meaningful Patient-Specific In Vitro Models to Study Brain DisordersA critical limitation of the field at present is the inherent difficulty in accurately defining cell states, particularly concerning the temporal and regional identity of pluripotent cells, neurons, and glial cells. A next step for hiPSC-based models of brain disorders will be building neural complexity in vitro, incorporating cell types and 3D organization to achieve network- and circuit-level structures. As the level of cellular complexity increases, new dimensions of modeling will emerge, and modeling neurological diseases that have a more complex etiology will be accessible. An important caveat to hiPSC-based models is the possibility that epigenetic factors and somatic mosaicism may contribute to neurological and neuropsychiatric disease, risk factors that may be difficult to capture in reprogramming or accurately recapitulate in vitro differentiation. A critical next step, in order to enable the use of hiPSCs for drug discovery, will be improving the scalability and reproducibility of in vitro differentiations and functional assays.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | 2018 | 29897633 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Abnormal synaptic architecture in iPSC-derived neurons from a multi-generational family with genetic Creutzfeldt-Jakob disease. | Gojanovich AD et al. | β | 2024 | β |
| A hominoid-specific signaling axis regulating the tempo of synaptic maturation. | Dong J et al. | β | 2024 | β |
| Dynamic Regulation OF The Chromatin Environment By Ash1L Modulates Human Neuronal Structure And Function | Jhanji M et al. | β | 2024 | β |
| Advances in microfluidic in vitro systems for neurological disease modeling. | Holloway PM et al. | β | 2021 | β |
| Brain Organoids: Tiny Mirrors of Human Neurodevelopment and Neurological Disorders. | Yadav A et al. | β | 2021 | β |
| Making Sense of Patient-Derived iPSCs, Transdifferentiated Neurons, Olfactory Neuronal Cells, and Cerebral Organoids as Models for Psychiatric Disorders. | Unterholzner J et al. | β | 2021 | β |
| Social epigenomics: are we at an impasse? | Non AL | β | 2021 | β |
| A collection of three integration-free iPSCs derived from old male and female healthy subjects. | RodrΓguez-Traver E et al. | β | 2020 | β |
| Development of two-photon polymerised scaffolds for optical interrogation and neurite guidance of human iPSC-derived cortical neuronal networks. | Crowe JA et al. | β | 2020 | β |
| Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells. | Tran J et al. | β | 2020 | β |
| High-throughput screening of human induced pluripotent stem cell-derived brain organoids. | Durens M et al. | β | 2020 | β |
| Human pluripotent stem cell-derived models and drug screening in CNS precision medicine. | Silva MC et al. | β | 2020 | β |
| Integration of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons into Rat Brain Circuits. | Yin X et al. | β | 2020 | β |
| JMJD3 and UTX determine fidelity and lineage specification of human neural progenitor cells. | Shan Y et al. | β | 2020 | β |
| Looking at neurodevelopment through a big data lens. | Briscoe J et al. | β | 2020 | β |
| Applying Deep Neural Network Analysis to High-Content Image-Based Assays. | Yang SJ et al. | β | 2019 | β |
| Cortical interneuron function in autism spectrum condition. | Lunden JW et al. | β | 2019 | β |
| Early Actions of Neurotransmitters During Cortex Development and Maturation of Reprogrammed Neurons. | Ojeda J et al. | β | 2019 | β |
| Human-Monkey Chimeras for Modeling Human Disease: Opportunities and Challenges. | De Los Angeles A et al. | β | 2019 | β |
| Mitochondria, Metabolism, and Redox Mechanisms in Psychiatric Disorders. | Kim Y et al. | β | 2019 | β |
| Neurons with Complex Karyotypes Are Rare in Aged Human Neocortex. | Chronister WD et al. | β | 2019 | β |
| Reconstitution of the Human Nigro-striatal Pathway on-a-Chip Reveals OPA1-Dependent Mitochondrial Defects and Loss of Dopaminergic Synapses. | Iannielli A et al. | β | 2019 | β |
| SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons. | Zaslavsky K et al. | β | 2019 | β |
| Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models. | Logan S et al. | β | 2019 | β |
| The effect of rho kinase inhibition on morphological and electrophysiological maturity in iPSC-derived neurons. | Harbom LJ et al. | β | 2019 | β |
| Thinking About Schizophrenia in an Era of Genomic Medicine. | Weinberger DR | β | 2019 | β |
| Challenges and ethical considerations for using cloned primates for human brain discovery. | Trounson AO et al. | β | 2018 | β |
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | Prytkova I et al. | β | 2018 | β |
| Human-Monkey Chimeras for Modeling Human Disease: Opportunities and Challenges. | De Los Angeles A et al. | β | 2018 | β |
| Single-cell analysis of diversity in human stem cell-derived neurons. | Harbom LJ et al. | β | 2018 | β |
| Small-molecule induction of AΞ²-42 peptide production in human cerebral organoids to model Alzheimer's disease associated phenotypes. | Pavoni S et al. | β | 2018 | β |
| The Efficacy of Graphene Foams for Culturing Mesenchymal Stem Cells and Their Differentiation into Dopaminergic Neurons. | Tasnim N et al. | β | 2018 | β |
| Tulsa 1000: a naturalistic study protocol for multilevel assessment and outcome prediction in a large psychiatric sample. | Victor TA et al. | β | 2018 | β |
| Understanding the role of steroids in typical and atypical brain development: Advantages of using a "brain in a dish" approach. | Adhya D et al. | β | 2018 | β |
| Using Automated Live Cell Imaging to Reveal Early Changes during Human Motor Neuron Degeneration. | Shin HY et al. | β | 2018 | β |
| An expandable embryonic stem cell-derived Purkinje neuron progenitor population that exhibits in vivo maturation in the adult mouse cerebellum. | Higuera GA et al. | β | 2017 | β |
| A novel system for correcting large-scale chromosomal aberrations: ring chromosome correction via reprogramming into induced pluripotent stem cell (iPSC). | Kim T et al. | β | 2017 | β |
| Application of CRISPR/Cas9 to the study of brain development and neuropsychiatric disease. | Powell SK et al. | β | 2017 | β |
| A Rapid Pipeline to Model Rare Neurodevelopmental Disorders with Simultaneous CRISPR/Cas9 Gene Editing. | Bell S et al. | β | 2017 | β |
| Brain imaging genetics in ADHD and beyond - Mapping pathways from gene to disorder at different levels of complexity. | Klein M et al. | β | 2017 | β |
| Genetic insights into the neurodevelopmental origins of schizophrenia. | Birnbaum R et al. | β | 2017 | β |
| Hallmarks of Alzheimer's Disease in Stem-Cell-Derived Human Neurons Transplanted into Mouse Brain. | Espuny-Camacho I et al. | β | 2017 | β |
| Human induced pluripotent stem cells as a research tool in Alzheimer's disease. | Robbins JP et al. | β | 2017 | β |
| iPhemap: an atlas of phenotype to genotype relationships of human iPSC models of neurological diseases. | Hollingsworth EW et al. | β | 2017 | β |
| Mitochondrial metabolism in early neural fate and its relevance for neuronal disease modeling. | Lorenz C et al. | β | 2017 | β |
| Neuronal Culture Microenvironments Determine Preferences in Bioenergetic Pathway Use. | SΓΌnwoldt J et al. | β | 2017 | β |
| Pluripotent stem cells in neuropsychiatric disorders. | Soliman MA et al. | β | 2017 | β |
| Proteasome impairment in neural cells derived from HMSN-P patient iPSCs. | Murakami N et al. | β | 2017 | β |
| Stem cell-derived neurons in the development of targeted treatment for schizophrenia and bipolar disorder. | Watmuff B et al. | β | 2017 | β |
| Building brains in a dish: Prospects for growing cerebral organoids from stem cells. | Mason JO et al. | β | 2016 | β |
| Complex Tissue and Disease Modeling using hiPSCs. | Passier R et al. | β | 2016 | β |
| Creation of a library of induced pluripotent stem cells from Parkinsonian patients. | Holmqvist S et al. | β | 2016 | β |
| Disease signatures for schizophrenia and bipolar disorder using patient-derived induced pluripotent stem cells. | Watmuff B et al. | β | 2016 | β |
| Dishing out mini-brains: Current progress and future prospects in brain organoid research. | Kelava I et al. | β | 2016 | β |
| Energy metabolism in neuronal/glial induction and in iPSC models of brain disorders. | Mlody B et al. | β | 2016 | β |
| Linking adult hippocampal neurogenesis with human physiology and disease. | Bowers M et al. | β | 2016 | β |
| The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders. | Millan MJ et al. | β | 2016 | β |
| Transcriptional Dynamics at Brain Enhancers: from Functional Specialization to Neurodegeneration. | Vermunt MW et al. | β | 2016 | β |